{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T09:58:36Z","timestamp":1792663116497,"version":"4.5.0"},"reference-count":53,"publisher":"Portland Press Ltd.","issue":"3","content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,2,14]]},"abstract":"<jats:p>We previously showed that medium chain acyl-coenzyme A dehydrogenase (MCAD, key regulator of fatty acid oxidation) is positively modulated in the heart by the cardioprotective kinase, phosphoinositide 3-kinase (PI3K(p110\u03b1)). Disturbances in cardiac metabolism are a feature of heart failure (HF) patients and targeting metabolic defects is considered a potential therapeutic approach. The specific role of MCAD in the adult heart is unknown. To examine the role of MCAD in the heart and to assess the therapeutic potential of increasing MCAD in the failing heart, we developed a gene therapy tool using recombinant adeno-associated viral vectors (rAAV) encoding MCAD. We hypothesised that increasing MCAD expression may recapitulate the cardioprotective properties of PI3K(p110\u03b1). rAAV6:MCAD or rAAV6:control was delivered to healthy adult mice and to mice with pre-existing pathological hypertrophy and cardiac dysfunction due to transverse aortic constriction (TAC). In healthy mice, rAAV6:MCAD induced physiological hypertrophy (increase in heart size, normal systolic function and increased capillary density). In response to TAC (~15 weeks), heart weight\/tibia length increased by ~60% in control mice and ~45% in rAAV6:MCAD mice compared with sham. This was associated with an increase in cardiomyocyte cross-sectional area in both TAC groups which was similar. However, hypertrophy in TAC rAAV6:MCAD mice was associated with less fibrosis, a trend for increased capillary density and a more favourable molecular profile compared with TAC rAAV6:control mice. In summary, MCAD induced physiological cardiac hypertrophy in healthy adult mice and attenuated features of pathological remodelling in a cardiac disease model.<\/jats:p>","DOI":"10.1042\/cs20171269","type":"journal-article","created":{"date-parts":[[2018,1,23]],"date-time":"2018-01-23T01:35:13Z","timestamp":1516671313000},"page":"381-397","update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Gene delivery of medium chain acyl-coenzyme A dehydrogenase induces physiological cardiac hypertrophy and protects against pathological remodelling"],"prefix":"10.1042","volume":"132","author":[{"given":"Bianca\u00a0C.","family":"Bernardo","sequence":"first","affiliation":[{"name":"Baker Heart and Diabetes Institute, Melbourne 3004, Australia"},{"name":"Department of Paediatrics, University of Melbourne, Parkville 3052, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate\u00a0L.","family":"Weeks","sequence":"additional","affiliation":[{"name":"Baker Heart and Diabetes Institute, Melbourne 3004, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thawin","family":"Pongsukwechkul","sequence":"additional","affiliation":[{"name":"Baker Heart and Diabetes Institute, Melbourne 3004, Australia"},{"name":"Department of Biochemistry and Molecular Biology, University of Melbourne, Parkville 3052, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoming","family":"Gao","sequence":"additional","affiliation":[{"name":"Baker Heart and Diabetes Institute, Melbourne 3004, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Kiriazis","sequence":"additional","affiliation":[{"name":"Baker Heart and Diabetes Institute, Melbourne 3004, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelly","family":"Cemerlang","sequence":"additional","affiliation":[{"name":"Baker Heart and Diabetes Institute, Melbourne 3004, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther\u00a0J.H.","family":"Boey","sequence":"additional","affiliation":[{"name":"Baker Heart and Diabetes Institute, Melbourne 3004, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yow\u00a0Keat","family":"Tham","sequence":"additional","affiliation":[{"name":"Baker Heart and Diabetes Institute, Melbourne 3004, Australia"},{"name":"Department of Medicine, Monash University, Clayton 3800, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chad\u00a0J.","family":"Johnson","sequence":"additional","affiliation":[{"name":"Monash Micro Imaging, Burnet Institute, Melbourne 3004, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwei","family":"Qian","sequence":"additional","affiliation":[{"name":"Baker Heart and Diabetes Institute, Melbourne 3004, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Jun","family":"Du","sequence":"additional","affiliation":[{"name":"Baker Heart and Diabetes Institute, Melbourne 3004, Australia"},{"name":"Department of Medicine, Monash University, Clayton 3800, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Gregorevic","sequence":"additional","affiliation":[{"name":"Baker Heart and Diabetes Institute, Melbourne 3004, Australia"},{"name":"Department of Physiology, University of Melbourne, Parkville 3052, Australia"},{"name":"Department of Biochemistry and Molecular Biology, Monash University, Clayton 3800, Australia"},{"name":"Department of Neurology, The University of Washington School of Medicine, Seattle, WA 98195, U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie\u00a0R.","family":"McMullen","sequence":"additional","affiliation":[{"name":"Baker Heart and Diabetes Institute, Melbourne 3004, Australia"},{"name":"Department of Medicine, Monash University, Clayton 3800, Australia"},{"name":"Department of Physiology, Monash University, Clayton 3800, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"288","published-online":{"date-parts":[[2018,2,8]]},"reference":[{"key":"2021113011034980500_B1","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/S0140-6736(14)61889-4","article-title":"The war against heart failure: the Lancet lecture","volume":"385","author":"Braunwald","year":"2015","journal-title":"Lancet North Am. Ed."},{"key":"2021113011034980500_B2","doi-asserted-by":"publisher","first-page":"e29","DOI":"10.1161\/CIR.0000000000000157","article-title":"Heart disease and stroke statistics\u20142015 update: a report from the American Heart Association","volume":"131","author":"Mozaffarian","year":"2015","journal-title":"Circulation"},{"key":"2021113011034980500_B3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ccl.2013.09.009","article-title":"Epidemiology of heart failure and scope of the problem","volume":"32","author":"Liu","year":"2014","journal-title":"Cardiol. Clin."},{"key":"2021113011034980500_B4","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1073\/pnas.0606663104","article-title":"Protective effects of exercise and phosphoinositide 3-kinase(p110alpha) signaling in dilated and hypertrophic cardiomyopathy","volume":"104","author":"McMullen","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021113011034980500_B5","doi-asserted-by":"publisher","first-page":"12355","DOI":"10.1073\/pnas.1934654100","article-title":"Phosphoinositide 3-kinase(p110alpha) plays a critical role for the induction of physiological, but not pathological, cardiac hypertrophy","volume":"100","author":"McMullen","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021113011034980500_B6","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1042\/CS20170063","article-title":"Phosphoinositide 3-kinase (p110\u03b1) gene delivery limits diabetes-induced cardiac NADPH oxidase and cardiomyopathy in a mouse model with established diastolic dysfunction","volume":"131","author":"Prakoso","year":"2017","journal-title":"Clin. Sci. (Lond.)"},{"key":"2021113011034980500_B7","doi-asserted-by":"publisher","first-page":"998","DOI":"10.2353\/ajpath.2009.090126","article-title":"Reduced phosphoinositide 3-kinase (p110alpha) activation increases the susceptibility to atrial fibrillation","volume":"175","author":"Pretorius","year":"2009","journal-title":"Am. J. Pathol."},{"key":"2021113011034980500_B8","doi-asserted-by":"publisher","first-page":"3369","DOI":"10.1007\/s00125-012-2720-0","article-title":"Enhanced phosphoinositide 3-kinase(p110alpha) activity prevents diabetes-induced cardiomyopathy and superoxide generation in a mouse model of diabetes","volume":"55","author":"Ritchie","year":"2012","journal-title":"Diabetologia"},{"key":"2021113011034980500_B9","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1161\/CIRCHEARTFAILURE.112.966622","article-title":"Phosphoinositide 3-kinase p110alpha is a master regulator of exercise-induced cardioprotection and PI3K gene therapy rescues cardiac dysfunction","volume":"5","author":"Weeks","year":"2012","journal-title":"Circ. Heart Fail."},{"key":"2021113011034980500_B10","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1161\/ATVBAHA.109.201988","article-title":"PI3K(p110\u03b1) protects against myocardial infarction-induced heart failure\/ Identification of PI3K-regulated miRNAs and mRNAs","volume":"30","author":"Lin","year":"2010","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"2021113011034980500_B11","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1152\/physrev.00043.2016","article-title":"Understanding key mechanisms of exercise-induced cardiac protection to mitigate disease: current knowledge and emerging concepts","volume":"98","author":"Bernardo","year":"2017","journal-title":"Physiol. Rev."},{"key":"2021113011034980500_B12","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1161\/01.CIR.0000091403.62293.2B","article-title":"Phosphoinositide 3-kinase gamma-deficient mice are protected from isoproterenol-induced heart failure","volume":"108","author":"Oudit","year":"2003","journal-title":"Circulation"},{"key":"2021113011034980500_B13","doi-asserted-by":"publisher","first-page":"910","DOI":"10.4161\/cc.6.8.4124","article-title":"PI3K(p110alpha) inhibitors as anti-cancer agents: minding the heart","volume":"6","author":"McMullen","year":"2007","journal-title":"Cell Cycle"},{"key":"2021113011034980500_B14","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/nrm2882","article-title":"The emerging mechanisms of isoform-specific PI3K signalling","volume":"11","author":"Vanhaesebroeck","year":"2010","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2021113011034980500_B15","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1038\/nrg1879","article-title":"The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism","volume":"7","author":"Engelman","year":"2006","journal-title":"Nat. Rev. Genet."},{"key":"2021113011034980500_B16","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/nrd2926","article-title":"Targeting the phosphoinositide 3-kinase pathway in cancer","volume":"8","author":"Liu","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"key":"2021113011034980500_B17","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s10545-010-9061-2","article-title":"A general introduction to the biochemistry of mitochondrial fatty acid beta-oxidation","volume":"33","author":"Houten","year":"2010","journal-title":"J. Inherit. Metab. Dis."},{"key":"2021113011034980500_B18","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1046\/j.1432-1033.2003.03947.x","article-title":"Mitochondrial beta-oxidation","volume":"271","author":"Bartlett","year":"2004","journal-title":"Eur. J. Biochem."},{"key":"2021113011034980500_B19","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.1161\/01.CIR.94.11.2837","article-title":"Fatty acid oxidation enzyme gene expression is downregulated in the failing heart","volume":"94","author":"Sack","year":"1996","journal-title":"Circulation"},{"key":"2021113011034980500_B20","doi-asserted-by":"publisher","first-page":"281389","DOI":"10.4061\/2009\/281389","article-title":"Medium-chain acyl-CoA dehydrogenase deficiency in an infant with dilated cardiomyopathy","volume":"2009","author":"Marci","year":"2009","journal-title":"Cardiol. Res. Pract."},{"key":"2021113011034980500_B21","doi-asserted-by":"publisher","first-page":"e1781","DOI":"10.1542\/peds.2013-1105","article-title":"Prolonged QTc interval in association with medium-chain acyl-coenzyme A dehydrogenase deficiency","volume":"133","author":"Wiles","year":"2014","journal-title":"Pediatrics"},{"key":"2021113011034980500_B22","doi-asserted-by":"publisher","first-page":"e23","DOI":"10.1371\/journal.pgen.0010023","article-title":"Medium-chain acyl-CoA dehydrogenase deficiency in gene-targeted mice","volume":"1","author":"Tolwani","year":"2005","journal-title":"PLoS Genet."},{"key":"2021113011034980500_B23","doi-asserted-by":"publisher","first-page":"22442","DOI":"10.1038\/srep22442","article-title":"Inhibition of miR-154 protects against cardiac dysfunction and fibrosis in a mouse model of pressure overload","volume":"6","author":"Bernardo","year":"2016","journal-title":"Sci. Rep."},{"key":"2021113011034980500_B24","doi-asserted-by":"publisher","first-page":"5097","DOI":"10.1096\/fj.14-253856","article-title":"Therapeutic silencing of miR-652 restores heart function and attenuates adverse remodeling in a setting of established pathological hypertrophy","volume":"28","author":"Bernardo","year":"2014","journal-title":"FASEB J."},{"key":"2021113011034980500_B25","doi-asserted-by":"publisher","first-page":"H2702","DOI":"10.1152\/ajpheart.00836.2004","article-title":"Regression of pressure overload-induced left ventricular hypertrophy in mice","volume":"288","author":"Gao","year":"2005","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"2021113011034980500_B26","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/nm1085","article-title":"Systemic delivery of genes to striated muscles using adeno-associated viral vectors","volume":"10","author":"Gregorevic","year":"2004","journal-title":"Nat. Med."},{"key":"2021113011034980500_B27","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1172\/JCI17459","article-title":"Activation of Mst1 causes dilated cardiomyopathy by stimulating apoptosis without compensatory ventricular myocyte hypertrophy","volume":"111","author":"Yamamoto","year":"2003","journal-title":"J. Clin. Invest."},{"key":"2021113011034980500_B28","doi-asserted-by":"publisher","first-page":"5705","DOI":"10.1038\/ncomms6705","article-title":"The small-molecule BGP-15 protects against heart failure and atrial fibrillation in mice","volume":"5","author":"Sapra","year":"2014","journal-title":"Nat. Commun."},{"key":"2021113011034980500_B29","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1093\/emboj\/19.11.2537","article-title":"The conserved phosphoinositide 3-kinase pathway determines heart size in mice","volume":"19","author":"Shioi","year":"2000","journal-title":"EMBO J."},{"key":"2021113011034980500_B30","doi-asserted-by":"publisher","first-page":"17615","DOI":"10.1073\/pnas.1206432109","article-title":"Therapeutic inhibition of the miR-34 family attenuates pathological cardiac remodeling and improves heart function","volume":"109","author":"Bernardo","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021113011034980500_B31","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nmeth.2019","article-title":"Fiji: an open-source platform for biological-image analysis","volume":"9","author":"Schindelin","year":"2012","journal-title":"Nat. Methods"},{"key":"2021113011034980500_B32","doi-asserted-by":"crossref","first-page":"e163","DOI":"10.1016\/j.ddstr.2013.10.001","article-title":"The yin and yang of adaptive and maladaptive processes in heart failure","volume":"9","author":"Bernardo","year":"2012","journal-title":"Drug Discov. Today Ther. Strateg."},{"key":"2021113011034980500_B33","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.pharmthera.2010.04.005","article-title":"Molecular distinction between physiological and pathological cardiac hypertrophy: experimental findings and therapeutic strategies","volume":"128","author":"Bernardo","year":"2010","journal-title":"Pharmacol. Ther."},{"key":"2021113011034980500_B34","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1007\/s00204-015-1477-x","article-title":"Pathophysiology of cardiac hypertrophy and heart failure: signaling pathways and novel therapeutic targets","volume":"89","author":"Tham","year":"2015","journal-title":"Arch. Toxicol."},{"key":"2021113011034980500_B35","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1152\/physiol.00043.2010","article-title":"The Athlete\u2019s heart vs. the failing heart: can signaling explain the two distinct outcomes?","volume":"26","author":"Weeks","year":"2011","journal-title":"Physiology"},{"key":"2021113011034980500_B36","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1161\/CIRCULATIONAHA.105.595231","article-title":"Akt1 is required for physiological cardiac growth","volume":"113","author":"DeBosch","year":"2006","journal-title":"Circulation"},{"key":"2021113011034980500_B37","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1126\/science.1210558","article-title":"Fatty acids identified in the Burmese python promote beneficial cardiac growth","volume":"334","author":"Riquelme","year":"2011","journal-title":"Science"},{"key":"2021113011034980500_B38","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1152\/physiolgenomics.00162.2010","article-title":"Whole transcriptome analysis of the fasting and fed Burmese python heart: insights into extreme physiological cardiac adaptation","volume":"43","author":"Wall","year":"2011","journal-title":"Physiol. Genomics"},{"key":"2021113011034980500_B39","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.cmet.2011.07.014","article-title":"Metabolic flux and the regulation of mammalian cell growth","volume":"14","author":"Locasale","year":"2011","journal-title":"Cell Metab."},{"key":"2021113011034980500_B40","doi-asserted-by":"publisher","first-page":"4782","DOI":"10.1074\/jbc.M310405200","article-title":"The insulin-like growth factor 1 receptor induces physiological heart growth via the phosphoinositide 3-kinase(p110alpha) pathway","volume":"279","author":"McMullen","year":"2004","journal-title":"J. Biol. Chem."},{"key":"2021113011034980500_B41","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1152\/physrev.1992.72.4.881","article-title":"Fatty acid homeostasis in the normoxic and ischemic heart","volume":"72","author":"van der Vusse","year":"1992","journal-title":"Physiol. Rev."},{"key":"2021113011034980500_B42","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1023\/A:1015332726303","article-title":"Gene regulatory mechanisms governing energy metabolism during cardiac hypertrophic growth","volume":"7","author":"Lehman","year":"2002","journal-title":"Heart Fail. Rev."},{"key":"2021113011034980500_B43","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1161\/CIRCULATIONAHA.111.075978","article-title":"Carnitine palmitoyltransferase-1b deficiency aggravates pressure overload-induced cardiac hypertrophy caused by lipotoxicity","volume":"126","author":"He","year":"2012","journal-title":"Circulation"},{"key":"2021113011034980500_B44","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1111\/dom.12248","article-title":"Inhibition of carnitine palymitoyltransferase1b induces cardiac hypertrophy and mortality in mice","volume":"16","author":"Haynie","year":"2014","journal-title":"Diabetes Obes. Metab."},{"key":"2021113011034980500_B45","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1002\/cphy.c150016","article-title":"Glucose transporters in cardiac metabolism and hypertrophy","volume":"6","author":"Shao","year":"2015","journal-title":"Compr. Physiol."},{"key":"2021113011034980500_B46","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1172\/JCI9056","article-title":"Deactivation of peroxisome proliferator-activated receptor-alpha during cardiac hypertrophic growth","volume":"105","author":"Barger","year":"2000","journal-title":"J. Clin. Invest."},{"key":"2021113011034980500_B47","doi-asserted-by":"publisher","first-page":"10086","DOI":"10.1073\/pnas.0603615103","article-title":"Transverse aortic constriction leads to accelerated heart failure in mice lacking PPAR-gamma coactivator 1alpha","volume":"103","author":"Arany","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021113011034980500_B48","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1161\/CIRCRESAHA.112.268128","article-title":"Cardiac-specific deletion of acetyl CoA carboxylase 2 prevents metabolic remodeling during pressure-overload hypertrophy","volume":"111","author":"Kolwicz","year":"2012","journal-title":"Circ. Res."},{"key":"2021113011034980500_B49","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1016\/S0140-6736(16)00082-9","article-title":"Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial","volume":"387","author":"Greenberg","year":"2016","journal-title":"Lancet"},{"key":"2021113011034980500_B50","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1001\/jamacardio.2016.0008","article-title":"Intracoronary gene transfer of adenylyl cyclase 6 in patients with heart failure: a randomized clinical trial","volume":"1","author":"Hammond","year":"2016","journal-title":"JAMA Cardiol."},{"key":"2021113011034980500_B51","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1093\/eurheartj\/ehv254","article-title":"Changes in ventricular remodelling and clinical status during the year following a single administration of stromal cell-derived factor-1 non-viral gene therapy in chronic ischaemic heart failure patients: the STOP-HF randomized Phase II trial","volume":"36","author":"Chung","year":"2015","journal-title":"Eur. Heart J."},{"key":"2021113011034980500_B52","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1161\/CIRCRESAHA.116.310039","article-title":"Introducing genes to the heart- all about delivery","volume":"120","author":"Hajjar","year":"2017","journal-title":"Circ. Res."},{"key":"2021113011034980500_B53","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1089\/hum.2016.166","article-title":"Randomized clinical trials of gene transfer for heart failure with reduced ejection fraction","volume":"28","author":"Penny","year":"2017","journal-title":"Hum. Gene Ther."}],"container-title":["Clinical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/clinsci\/article-pdf\/132\/3\/381\/446405\/cs-2017-1269.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/clinsci\/article-pdf\/132\/3\/381\/446405\/cs-2017-1269.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T11:58:19Z","timestamp":1638273499000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/clinsci\/article\/132\/3\/381\/72123\/Gene-delivery-of-medium-chain-acyl-coenzyme-A"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,8]]},"references-count":53,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,2,14]]}},"URL":"https:\/\/doi.org\/10.1042\/cs20171269","relation":{},"ISSN":["0143-5221","1470-8736"],"issn-type":[{"value":"0143-5221","type":"print"},{"value":"1470-8736","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,8]]}}}